Insmed (INSM) Stock Price

Insmed Price

NASDAQ·CLOSED
131.10USD-1.45 (-1.10 %)
Market closed

Revenue has compounded at 40.2% per year over the past 19 years to 606.42 M USD. Insmed's net margin stands at -210.5%, up from -230.6% several years earlier. Analysts set a median price target of 217.77 USD, implying 66.1% above the current price. Of 27 analysts, 25 rate the stock a buy — an overall Buy consensus. The stock trades about 39% above its 52-week low.

Insmed stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Insmed over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Insmed stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Insmed's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Insmed Stock Price History
DateInsmed Price
8/7/2026131.10 USD
8/6/2026132.55 USD
8/5/2026100.37 USD
8/4/202699.03 USD
8/3/202698.45 USD
7/31/202698.60 USD
7/30/2026101.49 USD
7/29/2026104.66 USD
7/27/2026106.77 USD
7/23/2026107.41 USD
7/22/2026106.64 USD
7/21/2026108.62 USD
7/20/2026107.02 USD
7/17/2026108.32 USD
7/16/2026107.46 USD
7/15/2026109.81 USD
7/14/2026110.11 USD
7/13/2026109.70 USD
7/10/2026115.61 USD
7/9/2026118.26 USD
7/8/2026113.28 USD
7/7/2026112.84 USD
7/6/2026111.18 USD
7/2/2026111.60 USD
7/1/2026107.00 USD
6/30/2026106.62 USD
6/29/2026104.20 USD
6/26/2026103.38 USD
6/25/2026104.47 USD
6/24/2026103.46 USD
6/23/2026102.15 USD
6/22/202698.10 USD
6/18/202696.36 USD
6/17/202698.15 USD
6/16/202693.98 USD
6/15/202698.09 USD
6/12/202697.17 USD
6/11/202696.88 USD
6/10/202694.46 USD
6/9/202699.04 USD
6/8/202694.17 USD
6/5/202699.84 USD
6/4/2026104.00 USD
6/3/2026103.01 USD
6/2/2026102.22 USD
6/1/2026103.96 USD
5/29/2026107.07 USD
5/28/2026108.79 USD
5/27/2026107.64 USD
5/26/2026107.94 USD
5/22/2026106.71 USD
5/21/2026108.00 USD
5/20/2026107.53 USD
5/19/2026107.41 USD
5/18/2026107.15 USD
5/15/2026109.14 USD
5/14/2026115.62 USD
5/13/2026117.99 USD
5/12/2026116.00 USD
5/11/2026103.89 USD
5/8/2026101.35 USD
5/7/2026105.00 USD
5/6/2026137.09 USD
5/5/2026139.44 USD
5/4/2026140.01 USD
5/1/2026133.26 USD
4/30/2026136.33 USD
4/29/2026135.03 USD
4/28/2026134.94 USD
4/27/2026135.98 USD
4/24/2026135.17 USD
4/22/2026144.48 USD
4/21/2026140.98 USD
4/20/2026142.82 USD
4/17/2026144.48 USD
4/16/2026142.79 USD
4/15/2026146.74 USD
4/14/2026153.40 USD
4/13/2026151.14 USD
4/10/2026154.81 USD
4/9/2026159.59 USD
4/8/2026160.18 USD
4/7/2026163.03 USD
4/6/2026163.81 USD
4/2/2026162.43 USD
4/1/2026164.86 USD
3/31/2026163.52 USD
3/30/2026153.32 USD
3/27/2026145.30 USD
3/26/2026147.60 USD
3/25/2026148.31 USD
3/24/2026139.14 USD
3/23/2026143.98 USD
3/20/2026136.00 USD
3/19/2026144.00 USD
3/18/2026142.70 USD
3/17/2026143.93 USD
3/16/2026144.60 USD
3/13/2026139.50 USD
3/12/2026139.52 USD
3/11/2026139.40 USD
3/10/2026143.85 USD
3/9/2026143.13 USD
3/6/2026140.13 USD
3/5/2026143.57 USD
3/4/2026149.88 USD
3/3/2026147.00 USD
3/2/2026146.32 USD
2/27/2026149.33 USD
2/26/2026150.00 USD
2/25/2026148.61 USD
2/24/2026158.62 USD
2/23/2026159.03 USD
2/20/2026164.91 USD
2/19/2026161.00 USD
2/18/2026151.11 USD
2/17/2026150.52 USD
2/13/2026148.75 USD
2/12/2026146.17 USD
2/11/2026148.43 USD
2/10/2026148.55 USD
2/9/2026149.54 USD
2/6/2026149.86 USD
2/5/2026151.03 USD
2/4/2026152.44 USD
2/3/2026157.16 USD
2/2/2026153.98 USD
1/30/2026156.87 USD
1/29/2026157.82 USD
1/28/2026155.89 USD
1/27/2026162.64 USD
1/26/2026159.72 USD
1/23/2026156.21 USD
1/22/2026160.39 USD
1/21/2026156.32 USD
1/20/2026163.51 USD
1/16/2026161.42 USD
1/15/2026159.27 USD
1/14/2026163.46 USD
1/13/2026163.72 USD
1/12/2026167.72 USD
1/9/2026175.97 USD
1/8/2026170.27 USD
1/7/2026176.00 USD
1/6/2026175.07 USD
1/5/2026175.20 USD
1/2/2026177.12 USD
12/31/2025174.04 USD
12/30/2025174.09 USD
12/29/2025176.34 USD
12/26/2025177.88 USD
12/24/2025177.42 USD
12/23/2025176.77 USD
12/22/2025175.76 USD
12/19/2025174.84 USD
12/18/2025166.55 USD
12/17/2025198.46 USD
12/16/2025200.67 USD
12/15/2025196.92 USD
12/12/2025197.01 USD
12/11/2025195.24 USD
12/10/2025189.85 USD
12/9/2025194.17 USD
12/8/2025196.55 USD
12/5/2025204.00 USD
12/4/2025205.04 USD
12/3/2025206.78 USD
12/2/2025206.60 USD
12/1/2025211.41 USD
11/28/2025207.77 USD
11/26/2025204.51 USD
11/25/2025209.02 USD
11/24/2025206.93 USD
11/21/2025198.76 USD
11/20/2025199.64 USD
11/19/2025203.56 USD
11/18/2025201.62 USD
11/17/2025197.40 USD
11/14/2025193.22 USD
11/13/2025190.96 USD
11/12/2025194.39 USD
11/11/2025193.69 USD
11/10/2025191.92 USD
11/7/2025189.70 USD
11/6/2025185.68 USD
11/5/2025186.88 USD
11/4/2025182.77 USD
11/3/2025186.23 USD
10/31/2025189.60 USD
10/30/2025194.22 USD
10/29/2025166.95 USD
10/28/2025165.29 USD
10/27/2025164.02 USD
10/24/2025159.66 USD
10/23/2025160.12 USD
10/22/2025160.40 USD
10/21/2025165.31 USD
10/20/2025167.91 USD
10/17/2025165.76 USD
10/16/2025163.19 USD
10/15/2025163.54 USD
10/14/2025161.38 USD
10/13/2025163.94 USD
10/10/2025162.33 USD
10/9/2025164.40 USD
10/8/2025161.81 USD
10/7/2025162.32 USD
10/6/2025158.28 USD
10/3/2025157.16 USD
10/2/2025152.80 USD
10/1/2025147.28 USD
9/30/2025144.01 USD
9/29/2025141.65 USD
9/26/2025137.03 USD
9/25/2025135.59 USD
9/24/2025141.00 USD
9/23/2025145.38 USD
9/22/2025145.03 USD
9/19/2025144.76 USD
9/18/2025145.86 USD
9/17/2025144.78 USD
9/16/2025144.75 USD
9/15/2025143.14 USD
9/12/2025145.93 USD
9/11/2025145.79 USD
9/10/2025145.93 USD
9/9/2025147.20 USD
9/8/2025146.68 USD
9/5/2025145.10 USD
9/4/2025142.53 USD
9/3/2025143.50 USD
9/2/2025145.30 USD
8/29/2025136.10 USD
8/28/2025134.97 USD
8/27/2025134.53 USD
8/26/2025132.17 USD
8/25/2025128.32 USD
8/22/2025131.88 USD
8/21/2025132.60 USD
8/20/2025129.45 USD
8/19/2025127.21 USD
8/18/2025127.27 USD
8/15/2025127.80 USD
8/14/2025127.75 USD
8/13/2025122.87 USD
8/12/2025122.00 USD
8/11/2025112.89 USD
Access this data via the Eulerpool API
Get Free API Key

Insmed Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
305.21 M USD
-670.76 M USD
-749.57 M USD
Jan 1, 2024
363.71 M USD
-825.15 M USD
-913.77 M USD
Jan 1, 2025
606.42 M USD
-1.19 B USD
-1.28 B USD
Jan 1, 2026 (e)
1.70 B USD
-1.70 B USD
-558.82 M USD
Jan 1, 2027 (e)
2.77 B USD
-2.77 B USD
71.54 M USD
Jan 1, 2028 (e)
3.78 B USD
-3.78 B USD
666.27 M USD
Jan 1, 2029 (e)
4.95 B USD
-4.95 B USD
1.44 B USD
Jan 1, 2030 (e)
6.27 B USD
-6.27 B USD
2.18 B USD

Insmed Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 12:25 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
–––0.010.140.160.190.250.310.360.611.702.773.784.956.27
––––1,411.1120.5914.6330.3224.4919.0266.94180.3663.2136.3930.8826.69
–––77.7882.3575.6176.6077.5578.3676.3179.3779.3779.3779.3779.3779.37
–––0.010.110.120.140.190.240.280.481.352.203.003.934.98
-0.12-0.17-0.19-0.30-0.23-0.26-0.40-0.46-0.67-0.83-1.19-1.70-2.77-3.78-4.95-6.27
–––-3,333.33-166.91-160.98-210.11-186.53-219.67-227.27-195.87-100.00-100.00-100.00-100.00-100.00
-0.12-0.18-0.19-0.32-0.25-0.29-0.43-0.48-0.75-0.91-1.28-0.560.070.671.442.18
49.3749.159.0968.75-21.6015.7547.6210.8355.7221.9039.76-56.27-112.72838.03115.6251.67
61.8161.9676.6077.1089.47102.30118.50132.69144.81179.02213.64213.64213.64213.64213.64213.64
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Insmed generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Insmed retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Insmed's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Insmed has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Insmed's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Insmed stock margins

The Insmed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Insmed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Insmed.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
76.57 %
-210.09 %
-230.63 %
Jan 1, 2022
77.53 %
-186.54 %
-196.26 %
Jan 1, 2023
78.52 %
-219.77 %
-245.59 %
Jan 1, 2024
76.43 %
-226.87 %
-251.24 %
Jan 1, 2025
79.41 %
-195.90 %
-210.54 %
Jan 1, 2026 (e)
79.41 %
-100.00 %
-32.89 %
Jan 1, 2027 (e)
79.41 %
-100.00 %
2.58 %
Jan 1, 2028 (e)
79.41 %
-100.00 %
17.62 %

Insmed Stock Revenue, EBIT, Earnings per Share

The Insmed earnings per share therefore indicates how much revenue Insmed has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.59 USD
-3.34 USD
-3.67 USD
Jan 1, 2022
1.85 USD
-3.45 USD
-3.63 USD
Jan 1, 2023
2.11 USD
-4.63 USD
-5.18 USD
Jan 1, 2024
2.03 USD
-4.61 USD
-5.10 USD
Jan 1, 2025
2.84 USD
-5.56 USD
-5.98 USD
Jan 1, 2026 (e)
7.97 USD
-7.95 USD
-2.62 USD
Jan 1, 2027 (e)
13.00 USD
-12.98 USD
0.34 USD
Jan 1, 2028 (e)
17.73 USD
-17.70 USD
3.12 USD

Insmed business model & stock analysis

Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life.

Insmed SWOT Analysis

Strengths

Insmed Inc has several strengths that contribute to its success. One major strength is its innovative product portfolio, which includes unique and effective treatments. The company's strong research and development capabilities allow it to continuously develop new products and stay ahead of the competition. Additionally, Insmed Inc has a strong financial position and a solid track record of revenue growth.

Weaknesses

Despite its strengths, Insmed Inc also faces some weaknesses that need to be addressed. One major weakness is its heavy reliance on key suppliers for raw materials and components. Any disruption in the supply chain can significantly impact the company's operations. Moreover, the company has limited geographical diversification, relying heavily on a few key markets for its revenue.

Opportunities

Insmed Inc has various opportunities to capitalize on. The increasing prevalence of chronic diseases presents a growing market for the company's products. By expanding its product portfolio and penetrating new geographic markets, Insmed Inc can further fuel its growth. Additionally, advancements in technology and the rise of digital healthcare open doors for the company to explore innovative solutions and enhance its market presence.

Threats

Insmed Inc faces certain threats that may impact its business. One significant threat is the intense competition within the pharmaceutical industry. The presence of well-established competitors with similar offerings poses a challenge to Insmed Inc's market share. Additionally, regulatory changes and stringent approval processes for new drugs can hinder the company's ability to bring products to market quickly.

Insmed Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Insmed Employees
Details
Date
Insmed Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Insmed Segments

Insmed Revenue by Segment (1/2)

  • Max

ARIKAYCE
BRINSUPRI
Details
Date
ARIKAYCE
BRINSUPRI
Jan 1, 2024
0.00 USD
0.00 USD
Jan 1, 2025
433.77 M USD
172.66 M USD

Insmed Revenue by Segment (2/2)

  • Max

Reportable Segment
Details
Date
Reportable Segment
Jan 1, 2024
363.71 M USD
Jan 1, 2025
606.42 M USD

Insmed Revenue by Region

  • 3 Years

  • Max

United States
International
Japan
Europe and rest of world
Details
Date
United States
International
Japan
Europe and rest of world
Jan 1, 2021
159.51 M USD
0.00 USD
16.01 M USD
12.95 M USD
Jan 1, 2022
185.99 M USD
0.00 USD
56.51 M USD
2.86 M USD
Jan 1, 2023
224.20 M USD
0.00 USD
65.73 M USD
15.28 M USD
Jan 1, 2024
254.80 M USD
0.00 USD
87.70 M USD
21.21 M USD
Jan 1, 2025
452.95 M USD
153.47 M USD
0.00 USD
0.00 USD

Insmed Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Insmed historical P/E ratio, EBIT multiple, and P/S ratio

Insmed annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Insmed shares outstanding

The number of shares of Insmed was 213.64 M in 2025. This indicates how many shares Insmed is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
118.50 M Stocks
Jan 1, 2022
132.69 M Stocks
Jan 1, 2023
144.81 M Stocks
Jan 1, 2024
179.02 M Stocks
Jan 1, 2025
213.64 M Stocks
Jan 1, 2026 (e)
213.64 M Stocks
Jan 1, 2027 (e)
213.64 M Stocks
Jan 1, 2028 (e)
213.64 M Stocks

Insmed stock splits

In Insmed's history, there have been no stock splits.

Current Insmed forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
92.59 % (25)
Hold
7.41 % (2)
Sell
0.00 % (0)
12M Price Target
217.77
Last Price
131.10
Currency
USD
12M Return Potential
66.11 %
LTM Return
0 %

Insmed Analyst Rating Actions

DateFirmActionRatingReliability
7/15/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
7/10/2026
Guggenheim
Guggenheim
MaintainedBuy30
6/22/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
6/8/2026
JP Morgan
JP Morgan
MaintainedOverweight80
6/5/2026
RBC Capital
RBC Capital
MaintainedOutperform52
5/14/2026
Truist Securities
Truist Securities
MaintainedBuy–
5/8/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
5/8/2026
RBC Capital
RBC Capital
MaintainedOutperform52
5/8/2026
Guggenheim
Guggenheim
MaintainedBuy30
4/17/2026
Roth Capital
Roth Capital
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Insmed Earnings Calls

2025

Insmed Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/5/2026-0.77USD-400.32 MUSD-2026 Q2
5/6/2026-0.98USD-309.28 MUSD-2026 Q1
2/19/2026-1.13USD-226.34 MUSD-2025 Q4
5/2/2024-1.20USD-83.26 MUSD-2024 Q1
2/21/2024-1.19USD-83.31 MUSD-2023 Q4
8/2/2023-1.03USD-83.08 MUSD-2023 Q2
5/3/2023-1.01USD-76.21 MUSD-2023 Q1
2/15/2023-1.03USD-72.18 MUSD-2022 Q4
10/27/2022-0.90USD-67.85 MUSD-2022 Q3
8/4/2022-0.91USD-60.30 MUSD-2022 Q2
...

EESG©

Eulerpool ESG Scorecard© for the Insmed stock

75/100
82
Environment
99
Social
45
Governance
E

Environment

20
Scope 1 - Direct Emissions1,109
Scope 2 - Indirect emissions from purchased energy1,122
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions2,230
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees53
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Insmed shareholder structure

% Name
11.32391%
JPMORGAN CHASE & CO
JPMORGAN CHASE & CO
7.87977%
DARWIN GLOBAL MANAGEMENT, LTD.
DARWIN GLOBAL MANAGEMENT, LTD.
7.82020%
BLACKROCK, INC.
BLACKROCK, INC.
6.17066%
FMR LLC
FMR LLC
4.86323%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
4.52109%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
...

Insmed Beneficial Ownership Filings (SEC 13D/G)

Free Float
91.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
10.80%
JPMORGAN CHASE & CO.
JPMORGAN CHASE & CO.
SEC ↗
9.39%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
7.90%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
7.80%
Darwin Global Management, Ltd.
Darwin Global Management, Ltd.
SEC ↗
7.70%
52-0556948
52-0556948
SEC ↗
6.70%
Janus Henderson Group plc
Janus Henderson Group plc
SEC ↗
6.60%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
6.10%
FMR LLC
FMR LLC
SEC ↗
5.79%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
5.70%
Dr. Abhishek Trehan
Dr. Abhishek Trehan
SEC ↗

Insmed Executives and Management Board

14 members · avg. age 60 · 43 % women

WL

Mr. William Lewis (56)

Chairman of the Board, Chief Executive Officer · since 2012

10.94 M USD

Management

RA

Mr. Roger Adsett (58)

Chief Operating Officer

4.26 M USD
MF

Dr. Martina Flammer (61)

Chief Medical Officer

4.11 M USD
SB

Ms. Sara Bonstein (44)

Chief Financial Officer

4.01 M USD
SS

Ms. S. Nicole Schaeffer (56)

Chief People Strategy Officer

2.66 M USD
MS

Mr. Michael Smith (48)

Chief Legal Officer

–
BD

Mr. Bryan Dunn

Vice President, Investor Relations · since 2025

–

Board of Directors

DB

Mr. David Brennan (71)

Lead Independent Director

435,000.00 USD
DM

Mr. David Mcgirr (70)

Independent Director

410,000.00 USD
LL

Mr. Leo Lee (55)

Independent Director

407,500.00 USD
CD

Dr. Clarissa Desjardins (58)

Independent Director

405,000.00 USD
CS

Ms. Carol Schafer (61)

Independent Director

405,000.00 USD
MS

Dr. Melvin Sharoky (74)

Independent Director · since 2001

402,500.00 USD

Insmed Supply Chain

Insmed Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
5 companies
#Nameβ 1YTrend
1
PPD, Inc.
Supplier·Customer·US
-0.46
-0.26
-0.47
-0.58
-0.25
—
—
2
AstraZeneca
Supplier·Customer·Pharmaceuticals·GB
0.39
0.73
-0.06
-0.46
-0.40
-0.67
-0.26
3
Ajinomoto
Supplier·Customer·Food Products·JP
0.41
0.76
0.81
0.62
-0.01
-0.55
-0.01
4
Thermo Fisher Scientific
Supplier·Customer·Life Sciences Tools & Services·US
0.29
0.65
0.62
0.79
0.34
-0.39
0.26
5
American Software A
Supplier·Software·US
0.03
0.79
0.67
0.73
0.81
-0.21
—

Frequently asked questions about Insmed

Insmed Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for patients with serious and rare diseases. The company's business model revolves around identifying unmet medical needs and utilizing innovative technologies to develop novel therapies. Insmed focuses on advanced lung diseases, including non-tuberculous mycobacterial lung disease (NTM) and severe bronchiectasis. By leveraging its expertise in this therapeutic area, Insmed aims to provide effective treatments to patients who lack adequate options. With a strong commitment to research and development, Insmed Inc strives to make a positive impact on the lives of patients and continually advance the field of biopharmaceuticals.

Insmed Inc is primarily active in the biopharmaceutical industry, specializing in the development and commercialization of novel therapies for patients with serious and rare diseases. With a focus on respiratory and infectious diseases, Insmed Inc aims to address unmet medical needs and improve the lives of patients. As a leading player in the biopharmaceutical sector, Insmed Inc is committed to advancing innovative solutions and creating value for shareholders, healthcare providers, and patients alike.

The main competitors of Insmed Inc in the market include other pharmaceutical companies such as Gilead Sciences, Novartis, AstraZeneca, and GlaxoSmithKline. These companies operate in the same industry and compete with Insmed Inc in the development and commercialization of innovative therapies. Their products and services may overlap with Insmed Inc's, creating competition for market share and the pursuit of specific indications and patient populations. By staying informed about the activities and progress of these competitors, investors can gain insights into the dynamic landscape of the pharmaceutical industry and make more informed investment decisions.

Insmed Inc is a biopharmaceutical company headquartered in Bridgewater, New Jersey. Founded in 1988, Insmed focuses on the development and commercialization of therapies for serious and rare diseases. The company primarily concentrates on the discovery and development of novel drugs to address unmet medical needs, particularly in the field of severe lung diseases. Over the years, Insmed has made significant advancements in scientific research and clinical trials, resulting in the approval of its flagship product, ARIKAYCE®, for the treatment of Mycobacterium avium complex lung disease. With a strong commitment to innovation and improving patients' lives, Insmed Inc has established itself as a leading player in the biopharmaceutical industry.

Insmed Inc, a leading biopharmaceutical company, has accomplished several significant milestones. In recent years, Insmed Inc received FDA approval for its breakthrough drug, ARIKAYCE®, a treatment for Mycobacterium avium complex (MAC) lung disease. This achievement marked a major breakthrough in respiratory medicine. Additionally, Insmed Inc has successfully advanced the development of novel therapies, such as brensocatib for bronchiectasis, establishing its position as a pioneer in the field. Through its dedication to scientific innovation and commitment to improving patient outcomes, Insmed Inc continues to achieve remarkable milestones, reinforce its reputation, and shape the future of the healthcare industry.

Insmed Inc is primarily present in the United States.

Insmed Inc is a leading biopharmaceutical company committed to transforming the lives of patients with serious and rare diseases. With a strong corporate philosophy centered around innovation, collaboration, and patient-centricity, Insmed strives to deliver breakthrough therapies that address unmet medical needs. The company values integrity, scientific excellence, and empathy, aiming to make a positive impact on the lives of patients worldwide. Insmed Inc focuses on developing advanced therapies using its proprietary platform technologies and leveraging its extensive industry knowledge and expertise. By constantly pushing boundaries and advocating for patients, Insmed embodies a commitment to improving healthcare outcomes and enhancing the quality of life for those in need.

Analysts currently set an average price target of 219.19 USD for the Insmed stock (median: 217.77 USD), implying +67.2 % versus the latest price. The consensus is based on 27 analyst ratings.

Insmed Analyst Price Targets 2026

27 analysts currently rate the Insmed stock: 25 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Insmed to generate revenue of 1.70 B USD and earnings per share of -2.62 USD.

Insmed Analyst Price Targets 2026

Converted at the current exchange rate, the Insmed share trades at 113.47 EUR (131.10 USD).

The Insmed share (INSM) is listed on 5 stock exchanges, including: NASDAQ (INSM), Frankfurt (IM8N.F), London (0JAV.L), London (0JAV.L), SIX (Zürich) (IM8N.SW).

Insmed Inc is a biopharmaceutical company focused on developing and marketing therapies for patients with rare lung diseases and serious infections. The company operates in three core business areas: product development, marketing of approved therapies, and diagnostic services. Insmed Inc invests heavily in research and development, particularly in the potential of inhalation drugs for targeted treatment of lung diseases such as cystic fibrosis and non-tuberculous mycobacterial infections. They also market approved therapies, like Arikayce, and offer diagnostic services with an innovative lung function diagnostic system. The goal of their business model is to create value for patients, doctors, and investors, positioning themselves as a leading company in this field. However, regulatory conditions may pose risks and delay the market entry of new therapies. Overall, Insmed Inc is an exciting company of great interest to investors and the medical community, contributing to saving lives and improving the quality of life for patients worldwide.

The expected revenue of Insmed is 1.70 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Insmed is -558.82 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Insmed is currently -50.12. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Insmed stock.

The price-to-sales ratio (P/S) of Insmed is currently 16.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Insmed stock.

The Eulerpool Quality Score for Insmed is 4/10.

The ISIN of Insmed is US4576693075. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Insmed is A1JJA3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Insmed is INSM. The ticker symbol is used to trade Insmed shares on the stock exchange.

Insmed paid dividends every year for the past 0 years.

Insmed is assigned to the 'Health' sector.

The dividends of Insmed are distributed in USD.

All fundamentals and in-depth analysis of Insmed

Our stock analysis for Insmed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Insmed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Insmed Stock
Insmed Revenue→
Insmed Stock
Insmed Net Income→
Insmed Stock
Insmed P/E→
Insmed Stock
Insmed P/S→
Insmed Stock
Insmed EBIT→
Insmed Stock
Insmed Dividend→
Insmed Stock
Insmed Directors Dealings→
Insmed Stock
Insmed Stocks→
Insmed Stock
Insmed Market capitalization→
Insmed Stock
Insmed Debt→
Insmed Stock
Insmed Liabilities→
Insmed Stock
Insmed Equity→
Insmed Stock
Insmed AAQS→
Insmed Stock
Insmed Employees→
Insmed Stock
Insmed ROE→
Insmed Stock
Insmed ROA→
Insmed Stock
Insmed ROCE→
Insmed Stock
Insmed News→
Insmed Stock
Insmed Analyst Price Targets→

Health Stocks

Inspecs GroupInsight Molecular DiagnosticsInspira Technologies Oxy BHNINOVIQInspiration Healthcare GroupInovio PharmaceuticalsInspire IVF PCLInovalon HoldingsInspire Medical SystemsInogenInspireMDInnovotechAll Stocks A–Z →